Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of ...

Helicore Biopharma has dosed the first subject in the randomised first-in-human Phase I trial of HCR-188 to treat obesity.

An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

A new study offers hope in the fight against flesh-eating fungus infections. Researchers have discovered a promising antibody ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being studied as an alternative to chemotherapy and radiotherapy. This is because it ...